European Journal of Rheumatology
Invited Review

Molecular “omic” signatures in systemic sclerosis

1.

Department of Molecular and Systems Biology, Geisel School of Medicine at Dartmouth, Hanover, NH, USA

2.

Department of Rheumatology, Allergy & Immunology, Yale School of Medicine, New Haven, CT, USA

3.

Department of Biomedical Data Science, Dartmouth College, Hanover, NH, USA

Eur J Rheumatol 2020; 7: Supplement S173-S180
DOI: 10.5152/eurjrheum.2020.19192
Read: 1783 Downloads: 866 Published: 27 October 2020

Systemic sclerosis (SSc) is a connective tissue disorder characterized by immunologic, vascular, and extracellular matrix abnormalities. Variation in the proportion and/or timing of activation in the deregulated molecular pathways that underlie SSc may explain the observed clinical heterogeneity in terms of disease phenotype and treatment response. In recent years, SSc research has generated massive amounts of “omics” level data. In this review, we discuss the body of “omics” level work in SSc and how each layer provides unique insight to our understanding of SSc. We posit that effective integration of genomic, transcriptomic, metagenomic, and epigenomic data is an important step toward precision medicine and is vital to the identification of effective therapeutic options for patients with SSc.

Cite this article as: Mehta BK, Espinoza ME, Hinchcliff M, Whitfield ML. Molecular “omic” signatures in systemic sclerosis. Eur J Rheumatol 2020; 7(Suppl 3): S173-80.

Files
EISSN 2148-4279